(PRESS RELEASE) CAMBRIDGE, 2-Aug-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish science-led biopharmaceutical company, has announced that its Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus … Read the full press release →
Posted in Healthcare, Marketing, News, Science, Technology, United Kingdom
Tagged AstraZeneca, bronchitis, corticosteroid, cough, cutaneous lupus erythematosus, Dr. Richard Furie, FDA, herpes zoster, infusion-related reactions, lupus, lupus nephritis, Mene Pangalos, MUSE Phase II trial, myositis, nasopharyngitis, OCS, oral corticosteroid, pathophysiology of lupus, Saphnelo, SLE, systemic lupus erythematosus, therapy, TULIP Phase III trials, type I IFN, type I interferon, upper respiratory tract infection